{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:03:26Z","timestamp":1777421006859,"version":"3.51.4"},"reference-count":30,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer recurrence in patients previously treated with radical prostatectomy and radiation therapy is challenging. Re-irradiation could be an option, but data regarding efficacy and safety are lacking. We retrospectively evaluated salvage re-irradiation for local recurrence after prostatectomy and external beam radiation therapy. We collected data from 48 patients who underwent salvage reirradiation with stereotactic radiation therapy for local prostate cancer recurrence in the prostatic bed at four French centers. Fifteen patients (31%) were on androgen deprivation therapy during stereotactic radiotherapy. Biochemical response and relapse-free survival were analyzed, and post-treatment toxicities were assessed according to the Common Terminology of Adverse Events criteria. Five patients had grade 3 late bladder toxicity (cystitis), three had grade 3 late incontinence, and one had grade 3 late chronic pain. At three months, 83% of patients had a positive biochemical response. The median follow-up was 22 months. At the end of the follow-up, 21 patients (43%) had a biochemical relapse. The median time to biologic relapse was 27 months. The biochemical relapse rates at 1 and 2 years were 80% and 52%, respectively. In conclusion, salvage re-irradiation for recurrent prostate cancer in the prostate bed may generate significant toxicity rates, and a prospective study with appropriate patient selection is needed to evaluate its effectiveness.<\/jats:p>","DOI":"10.3390\/cancers13174339","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T09:53:23Z","timestamp":1630058003000},"page":"4339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Stereotactic Re-Irradiation for Local Recurrence after Radical Prostatectomy and Radiation Therapy: A Retrospective Multicenter Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-2271","authenticated-orcid":false,"given":"Tanguy","family":"Perennec","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest, Boulevard J. Monod, 44800 St-Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-0693","authenticated-orcid":false,"given":"Loig","family":"Vaugier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest, Boulevard J. Monod, 44800 St-Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Toledano","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Radioth\u00e9rapie et Radiochirurgie Hartmann, 92300 Levallois, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Scher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Radioth\u00e9rapie et Radiochirurgie Hartmann, 92300 Levallois, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Thomin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Bretonneau Hospital, 37000 Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoann","family":"Pointreau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Jean Bernard\u2014Institut Inter-R\u00e9gionaL de Canc\u00e9rologie (ILC), 72000 Le Mans, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Janoray","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Bretonneau Hospital, 37000 Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"De Crevoisier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute Eugene Marquis, 35000 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest, Boulevard J. Monod, 44800 St-Herblain, France"},{"name":"Centre de Recherche en Canc\u00e9rologie Nantes-Angers (CRCNA), UMR 892 Inserm\u20146299 CNRS, Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, 8 Quai Moncousu, BP 70721, CEDEX 1, 44007 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_3","unstructured":"Mottet, N., Van den Bergh, R.C.N., Briers, E., Cornford, P., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A.M., and Lam, T.B. (2020). EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Eur. Assoc. Urol., 1\u2013182."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","article-title":"Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years","volume":"164","author":"Amling","year":"2000","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","article-title":"Long-term Biochemical Disease-free and Cancer-specific Survival Following Anatomic Radical Retropubic Prostatectomy: The 15-Year Johns Hopkins Experience","volume":"28","author":"Han","year":"2001","journal-title":"Urol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): A 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000000295","article-title":"Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO\/AUA Guideline Amendment 2018\u20132019","volume":"202","author":"Pisansky","year":"2019","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ctrv.2018.09.006","article-title":"Management of non-metastatic castrate-resistant prostate cancer: A systematic review","volume":"70","author":"Loriot","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen Deprivation Therapy for Prostate Cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"ref_14","first-page":"286","article-title":"Hypofractionated radiation therapy for prostate cancer: Biologic and technical considerations","volume":"2","author":"Sanfilippo","year":"2014","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited\u2014An analysis of clinical results from 14,168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol."},{"key":"ref_16","unstructured":"(2021, July 18). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin. Trials"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection\u2014A review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fonc.2019.00071","article-title":"Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results","volume":"9","author":"Olivier","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00345-015-1613-5","article-title":"CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed","volume":"34","author":"Detti","year":"2016","journal-title":"World J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zerini, D., Jereczek-Fossa, B.A., Fodor, C., Bazzani, F., Maucieri, A., Ronchi, S., Ferrario, S., Colangione, S.P., Gerardi, M.A., and Caputo, M. (2015). Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer. Br. J. Radiol., 88.","DOI":"10.1259\/bjr.20150197"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4149\/neo_2018_180723N520","article-title":"Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: Something ventured, something gained","volume":"66","author":"Volpe","year":"2019","journal-title":"Neoplasma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ijrobp.2019.02.041","article-title":"Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy","volume":"104","author":"Mancosu","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2017.11.007","article-title":"Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer","volume":"30","author":"Loi","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.5301\/tj.5000251","article-title":"Stereotactic Body Radiation Therapy Salvage Reirradiation of Radiorecurrent Prostatic Carcinoma Relapsed in the Prostatic Bed","volume":"101","author":"Arcangeli","year":"2015","journal-title":"Tumori J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skelet. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1097\/RLU.0000000000002794","article-title":"Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET\/CT in Biochemically Relapsed Prostate Cancer","volume":"44","author":"Dziuk","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Paymani, Z., Rohringer, T., Vali, R., Loidl, W., Alemohammad, N., Geinitz, H., Langsteger, W., and Beheshti, M. (2020). Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET\/CT in Prostate Cancer: A Comparative Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072308"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.eururo.2020.11.012","article-title":"Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy","volume":"79","author":"Knipper","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brachy.2020.07.001","article-title":"Salvage low-dose-rate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review","volume":"20","author":"Roy","year":"2021","journal-title":"Brachytherapy"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:42Z","timestamp":1760165622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":30,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174339"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174339","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}